Real-world data show reduction in use of urate-lowering therapy among people with type 2 diabetes using SGLT2 inhibitors.
WASHINGTON, DC — Use of sodium-glucose cotransporter-2 inhibitors reduced the need for urate-lowering therapy and gout flare therapies in people who had both type 2 diabetes and gout, new research has found.
The first agent of the SGLT2i class, dapagliflozin, was initially approved in the United States a decade ago for treating T2D. Since then, several other “flozins” have become available, and some have also received additional indications for heart failure and albuminuric chronic kidney disease.
Propensity score matching was conducted for demographics including age, race, and sex; comorbidities; use of emergency, inpatient, and critical care services; medications; labs; and body mass index. That yielded 11,800 individuals each in the SGLT2i and GLP-1 RA groups.
SGLT2 Inhibitors Sodium-Glucose Transporter-2 Inhibitors Sodium-Glucose Co-Transporter-2 Inhibitors Sodium-Glucose Cotransporter-2 Inhibitors Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Washington DC Washington - District Of Columbia Heart Polypharmacy Washington Electronic Medical Record EMR Electronic Health Record EHR
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study saysThe active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.
Read more »
Popular diabetes and weight-loss drug may reduce risk of Alzheimer's diseaseResearchers have found that semaglutide may lower the risk of Alzheimer's disease in people with type 2 diabetes (T2D).
Read more »
UNT Called Out by Free Expression Group for Extreme DEI Ban EffortsThe school just removed 'gender,' 'race,' 'class,' and 'equity' from many class titles and descriptions.
Read more »
Healthy Returns: Weight loss, diabetes drugs may reduce alcohol and opioid useGLP-1 drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by around half. Meanwhile, tech companies are talking the future of AI in health…
Read more »
Oral Semaglutide May Boost Liver Health in Type 2 DiabetesOral semaglutide improved liver health, diabetes status, and lipid profile in patients with MASLD and T2D, with weight loss likely playing a role, showed a prospective study.
Read more »
New First-in-Class Drug Approved for Advanced Stomach CancerThe FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
Read more »